SKM104-MA-L2 / SKYMAB Biotherapeutics - LARVOL DELTA

GPCR1 as a selective target in pancreatic cancer: Preclinical efficacy and safety of first-in-class SKM104-MA-L2, a topoisomerase-based antibody-drug conjugate with high therapeutic index (ESMO-GI 2025) - "Although ENHERTU® has demonstrated activity as the first tumor-agnostic ADC in HER2-positive metastatic solid tumors, including in HER2-high PDAC, its clinical benefit in this setting remains modest. GPCR1 is a highly selective and abundant therapeutic target in PDAC. Our data support the clinical development of SKM104-MA-L2 as a novel ADC candidate, opening new therapeutic avenues for topoisomerase I inhibitor-based ADCs in pancreatic cancer a setting where irinotecan-based therapies have long been part of standard care."

Preclinical • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HER-2